|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 2215 CONSTITUTION AVENUE, NW |
Address2 | |
City | WASHINGTON |
State | DC |
Zip Code | 20037-2985 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 3071-12
|
||||||||
|
6. House ID# 316200000
|
TYPE OF REPORT | 8. Year | 2009 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Allison C. Wiley, Political Action Coordinator |
Date | 10/19/2009 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
S266 - Medicare Prescription Drug Gap Reduction Act of 2009
HR203 - Medicare Fraud Prevention Act of 2009
HR27 - Medicare Fraud Prevention and Enforcement Act of 2009
Under Line 17: We would like to include the Office of the National Coordinator for Health Information Technology
HR616/S511 - Access to Durable Medical Equipment Act
HR574/S254 - Medicare Home Infusion Therapy Coverage Act of 2009
HR2560/S1131 - Independence At Home Act
HR1970/S956 - Preserve Patient Access to the Reputable DMEPOS Providers Act of 2009
HR3700/S1951 - Fair Medicaid Drug Payment Act (From 110th Congress)/Concept to Include Medicaid Average Manufacturers Price Reimbursement Formula in Health Care Reform
HR3108 - Medication Therapy Managament Benefits Act of 2009/Concept to Include Medication Therapy Management Provisions in Health Care Reform
HR3663 - Amends the Social Security Act to delay the October 1, 2009 deadline on which the accreditation requirement under the Medicare Program applies to suppliers of durable medical equipment that are pharmacies.
S683 - Community Choice Act of 2009
HR1392/S1221 - Amends the Social Security Act to ensure more appropriate payment amounts for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt pay discounts extended to wholesalers from the manufacturer's average sales price
(Public Law 110-275) Medicare Improvements for Patients and Providers Act of 2008 sections on Medicare DMEPOS
(Docket Number: CMS1561IFC) Medicare Program; Changes to the Competitive Acquisition of Certain Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) by Certain Provisions of the Medicare Improvements for Patients and Providers Act of 2008 (MIPPA)
(Docket Number: CMS-1540-F) Medicare Program; Inpatient Rehabilitation Facility Prospective Payment System for Federal Fiscal Year 2007; Certain Provisions Concerning Competitive Acquisition for Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS); Accreditation of DMEPOS Suppliers
(Docket Number: CMS-6006-F) Medicare Program: Surety Bond Requirement for Suppliers of Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS)
[Document Number: CMS-10260 (OMB#: 0938-1051)] Collection Activities; Medicare Advantage and Prescription Drug Program: Final Marketing Provisions
(74 FR 45206) HRSA Notice Regarding 340B Pricing Program - Children's Hospitals
(74 FR 28937) ONC Draft Recommendations for the Term "Meaningful Use" of Electronic Health Records
CMS August 2009 Memo: Fraud, Waste and Abuse (FWA) Training Clarification (regarding changes to 42 C.F.R. 422.503(b)(4)(vi) and 42 C.F.R. 423.504 (b)(4)(vi))
Final 2010 Medicare Part D Call Letter
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), White House Office, Indian Health Service
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kristina |
Lunner |
|
|
|
Marcie |
Bough |
|
Former Legislative Assistant |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
HR1204 - The Community Pharmacy Fairness Act of 2009
S80 - Pharmaceutical Market Access Act of 2009
HR1298/S525 - Pharmaceutical Market Access and Drug Safety Act of 2009
HR163 - Prescription Drug Affordability Act
HR2400 - Strategies to Address Antimicrobial Resistance Act
HR1706 - Protecting Consumer Access to Generic Drugs Act of 2009
HR3018 - Amend the Controlled Substance Act to address the use of intrathecal pumps
(Docket Number: FDA-2008-P-0380) Citizen Petition: Requesting a FDA Action on a "One Document Solution" for all Pharmacy-Based Communications
(Docket Number FDA2008N0038) Risk Communication Advisory Committee; Notice of Meeting on the types of communications that patients receive at the pharmacy includes: medication guides; patients package inserts; and consumer medication information
(Docket Number FDA2009D0181) Draft Guidance for Industry on Label Comprehension Studies for Nonprescription Drug Products;Availability
(Docket Number FDA2009N0295) Providing Effective Information to Consumers About Prescription Drug Risks and Benefits; Public Workshop
(Docket Number FDA1977N0013) (formerly Docket No. 1977N0094L) Organ-Specific Warnings; Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use; Final Monograph
(Docket Number FDA2009N0143) Risk Evaluation and Mitigation Strategies for Certain Opioid Drugs; Notice of Public Meeting
(Docket Number FDA2006N0238) (formerly Docket No. 2006N0062) Expanded Access to Investigational Drugs for Treatment Use
(Docket Number FDA2006N0237) (formerly Docket No. 2006N0061) Charging for Investigational Drugs Under an Investigational New Drug Application
(Docket Number FDA2009N0247) Food and Drug Administration Transparency Task Force; Reopening of Comment Period
(Docket Number DEA321a) Identification of Institution-based Individual Practitioners
(Docket Number FDA2009N0374) Educating the Public About Removal of Essential-Use Designation for Epinephrine; Public Workshop; Request for Comments
(Docket Number FDA2009N0441) Promotion of Food and Drug Administration-Regulated Medical Products Using the Internet and Social Media Tools; Notice of Public Hearing
(Docket Number FDA-2009-N-0138) Liver Injury Related to the Use of Acetaminophen; Joint Meeting of the Drug Safety and Risk Management Advisory Committee, Nonprescription Drugs Advisory Committee and the Anesthetic and Life Support Drugs Advisory Committee
(DEA Information Collection 1117-0046) Self-Certification, Training and Logbooks for Regulated Sellers of Scheduled Listed Chemical Products
Concept - Oppose Liberalizing Prescription Drug Importation
Concept - Misuse of Antibiotics in Agriculture
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, White House Office, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kristina |
Lunner |
|
|
|
Marcie |
Bough |
|
Former Legislative Assistant |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
HR756/S660 - National Pain Care Policy Act of 2009
HR179 - Community AIDS and Hepatitis Prevention Act
S1213 - A bill to amend title XI of the Social Security Act to provide for the conduct of comparative effectiveness research.
Under Line 17: We would like to include the Agency for Healthcare Research and Quality (AHRQ)
HR2891 - Access to Frontline Health Care Act of 2009
HR1259 - Dextromethorphan Distribution Act of 2009
HR1256 - Family Smoking Prevention and Tobacco Control Act on smoking cessation, advertising and marketing of tobacco products; and sale and distribution of tobacco.
HR2345 - Amends the Fair Credit Reporting Act to provide for an exclusion from Red Flag Guidelines for health care practices
S256 - Combat Methamphetamine Enhancement Act of 2009
S750 - Caring for an Aging America Act
S1213 - Patient-Centered Outcomes Research Act of 2009
HR676 - U.S. National Health Insurance Act on the inclusion of medication therapy management services
S1679 & Draft Bill Affordable Health Choices Act (Sections on ensuring quality of care; affordable choices of health benefit plans; seeking the best medical advice; spending for Federally Qualified Health Centers (FQHCs); national strategy; presentation of drug information; center for health outcomes research and evaluation; administrative simplification; right choices program; grants to establish community health teams to support a medical home model; grants to implement medication management services in treatment of chronic disease; national health care workforce commission; funding for National Health Service Corps; geriatric education and training, career awards, comprehensive geriatric education; nurse education, practice, and retention grants; increasing Access to Clinical Preventive Services, and increase prevention and wellness provisions)
HR3200 & Draft Bill - America's Affordable Health Choices Act of 2009 [Sections on ensuring adequacy of provider networks; essential benefits package defined; Health Benefits Advisory Committee; outreach and enrollment of exchange-eligible individuals and employers in Exchange-participating health benefits plan; payment rates for items and services; reducing potentially preventable hospital readmissions; post acute care services payment reform plan; requiring drug manufacturers to provide drug rebates for certain, full premium subsidy eligible individuals; phasedin elimination of coverage gap; repeal of provision relating to submission of claims by pharmacies located in or contracting with long-term care facilities; including costs incurred by AIDS drug assistance programs and Indian Health Service in providing prescription drugs toward the annual out of pocket threshold under part D; permitting mid-year changes in enrollment; telehealth expansion and enhancements; intelligent assignment in enrollment; ensuring effective communication in Medicare; Accountable Care Organization pilot program; medical home pilot program; coverage and waiver of cost-sharing for preventive services; comparative effectiveness research; reports on financial relationships between manufacturers and distributors of covered drugs, devices, biologicals, or medical supplies under Medicare, Medicaid, or CHIP and physicians and other health care entities and between physicians and other health care entities; distribution of unused residency positions; require providers and suppliers to adopt programs to reduce waste, fraud, and abuse; payments to pharmacists; Task Force on Clinical Preventive Services; fully integrated dual eligible special needs plans (FIDESNP); public health and workforce development; prevention and wellness; preventive cost sharing services; Butterfield Amendment - Establishes an Medication Therapy Management Grant Program (House Engery and Commerce Committeee's HR3200); Weiner Amendment - Creates PBM Transparency (House Engery and Commerce Committeee's HR3200); and Schakowsky Amendment - Allows direct price negotiations in Medicare Part D (House Engery and Commerce Committeee's HR3200)]
Draft Bill Access to Birth Control Act
Chairman's Mark - America's Healthy Future Act of 2009 [sections on health care coverage including sections on the Health Benefits Advisory Committee, making coverage affordable, Medicaid coverage for the lowest income populations, Medicaid prescription drug coverage, changes to Medicaid payment for prescription drugs (AMP); Medicaid quality; promoting disease prevention and wellness including sections on Medicare (annual wellness visit, study on beneficiary access to immunizations, removing barriers to preventive services, and incentives for healthy lifestyles) and Medicaid (improving access to preventive services for eligible adults, incentives for healthy lifestyles, and Medicaid state plan option promoting health homes and integrated care); improving the quality and efficiency of health care including sections on physician value-based purchasing, quality infrastructure, Accountable Care Organizations, CMS Innovation Center; strengthening primary care and other workforce improvements; Medicare Part D improvements including sections improving coverage in the Part D coverage gap, facilitation of reassignments of beneficiaries in low-income subsidy plans, strengthening formularies with respect to certain categories or classes of drugs, and limitation on removal or change of coverage of covered Part D drugs under a formulary; Medicare Advantage including section on Medicare Advantage payment; home health payment changes including section on Durable Medical Equipment; improving Medicare for patients and providers including sections on Medicare Diabetes Self-Management Training, revisions to demonstration project on community health integration models in certain rural counties; administrative simplification including section on changes to HIPAA;ensuring Medicare sustainability including section on Medicare Commission; transparency and program integrity including sections on physician payment sunshine and prescription drug samples; fraud, waste, and abuse including sections on provider screening, provider compliance and penalties; revenue items including sections on employer health insurance reporting, annual fee on clinical laboratories; the inclusion of PBM transparency and the medications therapy management grant program in section 213 of S1679; and changes to long-term care pharmacy utilization management provisions]
Concept - Role of Pharmacist-Provided Patient Care Services in any Integrated Care Model, Hospital Readmissions and Medication Therapy Management Services in Health Care Reform
Concept - Include Pharmacists and Pharmacies in 2009 H1N1 and seasonal flu immunization activities
(Docket No. FDA2009N0294) Regulation of Tobacco Products; Request for Comments
AHRQ Proposed Collection Project: Health IT Community Tracking Study 2009
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, White House Office, Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), Centers For Disease Control & Prevention (CDC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kristina |
Lunner |
|
|
|
Marcie |
Bough |
|
Former Legislative Assistant |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
HR3239 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2010
sections on Medicare, Medicaid, SCHIP, emergency preparedness, AIDS assistance programs, CDC, and ONC funds
Under Line 17: We would like to include the Office of the National Coordinator for Health Information Technology
S1391 - Department of Defense Authorization Act for Fiscal Year 2010 section on eliminating funds to prevent prescription drug importation (S.AMDT 1467)
(Public Law 111-5) American Recovery and Reinvestment Act of 2009 sections on Health Information Technology
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kristina |
Lunner |
|
|
|
Marcie |
Bough |
|
Former Legislative Assistant |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code VET
16. Specific lobbying issues
Concept - veterans' prescription drug benefit and the importance of medication therapy management services
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kristina |
Lunner |
|
|
|
Marcie |
Bough |
|
Former Legislative Assistant |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |